trastuzumab,capecitabine,tucatinib
Seagen
['t-dxd', 'tucatinib']
helpful real-world data from france looking at the activity of the tucatinib triplet after progression on t-dxd. n=101, median of 4 prior lines. median pfs 4.7 months, median os 13 months, expectedly shorter than what seen in her2climb. #asco23 
Medical Oncologist, Research Fellow @DanaFarber | @Harvard | PhD @LaStatale | former @IEOufficiale. Interested in breast oncology, HER2, ADCs & good music.